Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 57 PAGES: 52

More Info
									               Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDME5575FSA                                                                                           Publication Date: APR 2013

          Landsteinerstr. 5                                  Phone              +49 6103 8010                   Revenue          422 (million EUR)
          Dreieich, Hessen                                   Fax                +49 6103 801150                 Net Profit       46.35 (million EUR)
          63303                                              Website            www.biotest.de                  Employees        1,707
          Germany                                            Exchange           BIO [XETRA]                     Industry         Medical Equipment

       Company Overview
       Biotest AG (Biotest) is a pharmaceutical and biotherapeutic drugs provider. The company develops, manufactures and distributes
       biological medical products through its value chain from preclinical and clinical development to sales. It specializes in the areas of
       clinical immunology, haematology and intensive medicine. The company operates its business through three operating segments
       namely, Therapy, Plasma & Services and Other Segments. Through Plasma & Services, it develops and distributes
       immunoglobulins, clotting factors and albumins based on human blood plasma. Therapy segment conducts clinical development
       of monoclonal antibodies, such as rheumatism and leukaemia.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Biotest AG, SWOT Analysis
         Dr. Gregor Schulz                   Chairman                                 Strengths                              Weaknesses
         Dr. Michael Ramroth                 Chief Financial Officer
                                                                                      Strong Global Presence                 Lack of Capital Resources
         Dr. Georg Floss                     Executive Vice President,
                                             Plasma Protein Operations                Focused Research and
                                                                                      Development
         Dr. Martin Reinecke                 Senior    Vice    President,
                                             Plasma     Alliances    and
                                             Protein Supply                           Opportunities                          Threats
         Dr. Monika Buttkereit               Head Investor Relations
                                                                                      Rheumatoid Arthritis                   Uncertain R&D Outcomes
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData
                                                                                      Growth in Emerging Economies Governmental Regulations
       Share Data
         Biotest AG                                                                  Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Share Price (EUR) as on 22-Apr-                                57.04
        2013
        EPS (EUR)                                                        1.57
        Market Cap (million EUR)                                         669
        Enterprise Value (million EUR)                                   748
        Shares Outstanding (million)                                       12
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 25, 2013         Biotest Reports Revenue Of €440m In 2012
                                                                                      Nov 13, 2012         Biotest Reports Revenue Of €324.9m For Nine
                                                                                                           Months Ended September 30, 2012
                                                                                      Aug 13, 2012         Biotest Reports Revenue Of €220.2m In H1
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review                                                                 Reference Code: GDME5575FSA
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Biotest AG - Key Facts ....................................................................................................................................................................... 5
       Biotest AG - Key Employees .............................................................................................................................................................. 6
       Biotest AG - Key Employee Biographies ............................................................................................................................................ 7
       Biotest AG - Major Products and Services ......................................................................................................................................... 8
       Biotest AG - Pharmaceutical Pipeline Products Data ......................................................................................................................... 9
          Biotest AG, Pipeline Products by Therapy Area ............................................................................................................................. 9
          Biotest AG, Pipeline Products by Development Phase ................................................................................................................. 10
       Biotest AG - History .......................................................................................................................................................................... 24
       Biotest AG - Company Statement .................................................................................................................................................... 26
       Biotest AG - Locations And Subsidiaries .......................................................................................................................................... 27
          Head Office ................................................................................................................................................................................... 27
          Other Locations & Subsidiaries ..................................................................................................................................................... 27
       Biotest AG - Key Manufacturing Facilities ........................................................................................................................................ 29
       Section 2 – Company Analysis ......................................................................................................................................................... 30
       Biotest AG - Business Description.................................................................................................................................................... 30
       Biotest AG - Corporate Strategy ....................................................................................................................................................... 31
       Biotest AG - SWOT Analysis ............................................................................................................................................................ 32
          SWOT Analysis - Overview........................................................................................................................................................... 32
          Biotest AG - Strengths .................................................................................................................................................................. 32
             Strength - Strong Global Presence ........................................................................................................................................... 32
             Strength - Focused Research and Development ...................................................................................................................... 32
          Biotest AG - Weaknesses ............................................................................................................................................................. 32
             Weakness - Lack of Capital Resources..................................................................................................................................... 32
          Biotest AG - Opportunities ............................................................................................................................................................ 32
             Opportunity - Rheumatoid Arthritis ............................................................................................................................................ 32
             Opportunity - Growth in Emerging Economies .......................................................................................................................... 33
          Biotest AG - Threats ..................................................................................................................................................................... 33
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 33
             Threat - Governmental Regulations .......................................................................................................................................... 33
             Threat - Competition and Technological Change ...................................................................................................................... 33
             Threat - Changing Diagnostic Market Conditions ...................................................................................................................... 34
       Biotest AG - Key Competitors........................................................................................................................................................... 35
       Section 3 – Company Financial Ratios ............................................................................................................................................. 36
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 36
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 36
       Performance Chart ........................................................................................................................................................................... 38
       Financial Performance...................................................................................................................................................................... 38
       Financial Ratios - Interim Ratios....................................................................................................................................................... 39
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 40
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 41
          Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................................................... 41



Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review                                                                                                 Reference Code: GDME5575FSA
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Biotest AG, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .......................................................................... 42
          Biotest AG, Medical Equipment, Deals By Year, 2007 to YTD 2013 ............................................................................................ 43
          Biotest AG, Medical Equipment, Deals By Type, 2007 to YTD 2013 ..............................................
								
To top